行情

JAZZ

JAZZ

爵士制药
NASDAQ

实时行情|Nasdaq Last Sale

109.75
+0.14
+0.13%
盘后: 109.75 0 0.00% 16:51 07/02 EDT
开盘
110.01
昨收
109.61
最高
111.70
最低
109.52
成交量
44.03万
成交额
--
52周最高
154.24
52周最低
86.88
市值
60.74亿
市盈率(TTM)
22.80
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测JAZZ价格均价为155.44,最高价位195.00,最低价为109.00。

EPS

JAZZ 新闻

更多
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The busy calendar of June proved positive for drug approvals, with most scheduled events producing positive outcomes. New molecular entity, or NME, approval for the month totaled two, taking the total NME approvals for the year to 24.
Benzinga · 2天前
Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors
Seeking Alpha - Article · 3天前
Nasdaq's $1.2 trln biotech index draws Europe's COVID drug hunters
Reuters · 3天前
Pharmamar Announces That It Has Received Payment of $100M From Jazz Pharmaceuticals for the Approval of Zepzelcatm (Lurbinectedin) in the U.s.
PharmaMar (MSE:PHM) has today announced that it has received payment of $100 million from Jazz Pharmaceuticals (NASDAQ: JAZZ), corresponding to the first part of the regulatory milestones, for the approval of lurbinectedin in the U.S. for the treatment of pati
Benzinga · 4天前
3 Reasons Jazz Pharmaceuticals Is A Hot Buy Right Now
MotleyFool.com · 06/23 11:06
BofA Raises Jazz Pharma Estimates After Zepzelca Update
Benzinga · 06/18 19:19
BofA Raises Jazz Pharma Estimates After Zepzelca Update
Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) provided encouraging updates on its commercial efforts in a recent conference call on the lung cancer drug Zepzelca, according to BofA Securities.
Benzinga · 06/18 18:20
B of A Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $167
B of A Securities maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $165 to $167.
Benzinga · 06/18 15:47

所属板块

制药
+0.58%
制药与医学研究
+0.61%

热门股票

代码
价格
涨跌幅

JAZZ 简况

Jazz Pharmaceuticals Public Limited Company是一家生物制药公司。该公司致力于开发和商业化解决未满足的医疗需求的产品。该公司拥有针对睡眠和血液学/肿瘤学领域的多元化产品与候选产品组合。该公司的主导市场产品包括治疗发作性嗜睡病患者猝倒和日间过度嗜睡(EDS)的Xyrem(羟丁酸钠口服溶液)、治疗急性淋巴细胞白血病(ALL)的Erwinaze和治疗重度肝静脉闭塞性疾病(VOD)的Defitelio(去纤苷)。该公司的其他候选产品包括治疗发作性嗜睡病中的EDS与阻塞性睡眠呼吸暂停(OSA)患者的EDS的JZP-110,以及治疗发作性嗜睡病中的EDS的JZP-386。
展开

微牛提供Jazz Pharmaceuticals PLC(NASDAQ-JAZZ)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的JAZZ股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易JAZZ股票基本功能。